Provided by Tiger Trade Technology Pte. Ltd.

Regeneron Pharmaceuticals

793.74
+12.251.57%
Post-market: 793.08-0.6600-0.08%19:45 EDT
Volume:591.28K
Turnover:468.41M
Market Cap:81.72B
PE:19.63
High:798.84
Open:791.98
Low:779.45
Close:781.49
52wk High:859.34
52wk Low:541.00
Shares:102.95M
Float Shares:98.88M
Volume Ratio:1.09
T/O Rate:0.60%
Dividend:3.64
Dividend Rate:0.46%
EPS(TTM):40.43
EPS(LYR):41.48
ROE:14.04%
ROA:6.53%
PB:2.58
PE(LYR):19.14

Loading ...

Regeneron Pharmaceuticals Inc. Stock Outperforms Competitors Despite Losses On The Day

Dow Jones
·
Jun 18

Regeneron Pharmaceuticals shareholders elect Class II directors at annual meeting

Reuters
·
Jun 18

Regeneron (REGN) Stock Valuation After WHO Ebola Trial Backing And Expanding R&D Collaborations

Simply Wall St.
·
Jun 13

Parabilis Medicines Closes Initial Public Offering

MT Newswires Live
·
Jun 12

Regeneron Pharmaceuticals Inc. Stock Underperforms Wednesday When Compared To Competitors

Dow Jones
·
Jun 11

BUZZ-Drug developer Parabilis Medicines surges in Nasdaq debut

Reuters
·
Jun 11

Parabilis Medicines to Raise $745 Million in IPO, Private Offering

MT Newswires Live
·
Jun 10

Regeneron declares Q2 2026 distribution of R$ 0.05 per unit, payable June 10

Reuters
·
Jun 09

Regeneron Pharmaceuticals Inc. Stock Slips 3.8%, Underperforms Peers

Dow Jones
·
Jun 09

Movement Alert|Regeneron Pharmaceuticals Falls 3.07% in Regular Trading, Phase 3 Clinical Failure and Eylea Biosimilar Threat Weigh on Shares

Market Focus
·
Jun 09

BUZZ - Nasdaq top and bottom performing stocks at about 11:01 a.m. EDT on 2026-06-08

Reuters
·
Jun 08

Regeneron Pharmaceuticals Inc. Stock Underperforms Friday When Compared To Competitors Despite Daily Gains

Dow Jones
·
Jun 06

Regeneron Pharmaceuticals (REGN) Valuation Check After CytomX Collaboration Expansion And Lynozyfic Trial Update

Simply Wall St.
·
Jun 05

Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO

GlobeNewswire
·
Jun 04

BRIEF-Parabilis Medicines - Estimated IPO Price Per Share Between $17 And $19 - SEC Filing

Reuters
·
Jun 04

Parabilis Medicines - Intends to Use About $150 Mln of IPO Proceeds to Continue Ongoing Clinical Development of Zolucatetide in Desmoid Tumors

THOMSON REUTERS
·
Jun 04

Parabilis Medicines Inc Says Regeneron Pharmaceuticals Agreed to Buy About $75 Mln of Co's Common Stock in Concurrent Private Placement

THOMSON REUTERS
·
Jun 04

Regeneron Pharmaceuticals Inc. Stock Underperforms Wednesday When Compared To Competitors Despite Daily Gains

Dow Jones
·
Jun 04

Movement Alert|Regeneron Pharmaceuticals Rises 3.07% in Regular Trading, WHO Ebola Antibody Recommendation and CytomX Partnership Expansion Boost Shares

Market Focus
·
Jun 04

BUZZ-U.S. STOCKS ON THE MOVE-USA Rare Earth, MiniMed, Rent the Runway

Reuters
·
Jun 03